NO20072289L - Karboksylerte pers-substituerte bicykliske forbindelser for okklusiv arteriesykdom - Google Patents
Karboksylerte pers-substituerte bicykliske forbindelser for okklusiv arteriesykdomInfo
- Publication number
- NO20072289L NO20072289L NO20072289A NO20072289A NO20072289L NO 20072289 L NO20072289 L NO 20072289L NO 20072289 A NO20072289 A NO 20072289A NO 20072289 A NO20072289 A NO 20072289A NO 20072289 L NO20072289 L NO 20072289L
- Authority
- NO
- Norway
- Prior art keywords
- pers
- carboxylated
- artery disease
- substituted bicyclic
- bicyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61820304P | 2004-10-12 | 2004-10-12 | |
PCT/US2005/036574 WO2006044415A2 (en) | 2004-10-12 | 2005-10-11 | Carboxylic acid peri - substituted bicyclics for occlusive artery disease |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072289L true NO20072289L (no) | 2007-07-06 |
Family
ID=35636923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072289A NO20072289L (no) | 2004-10-12 | 2007-05-02 | Karboksylerte pers-substituerte bicykliske forbindelser for okklusiv arteriesykdom |
Country Status (13)
Country | Link |
---|---|
US (1) | US7714017B2 (es) |
EP (1) | EP1814881A2 (es) |
JP (1) | JP2008515981A (es) |
CN (1) | CN101076531A (es) |
AU (1) | AU2005295821A1 (es) |
CA (1) | CA2583828A1 (es) |
IL (1) | IL182490A0 (es) |
MX (1) | MX2007004527A (es) |
NO (1) | NO20072289L (es) |
NZ (1) | NZ554492A (es) |
RU (1) | RU2007115522A (es) |
SG (1) | SG156636A1 (es) |
WO (1) | WO2006044415A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20070220A1 (es) * | 2005-07-29 | 2007-03-19 | Wyeth Corp | Proceso para la sintesis de moduladores del receptor de progesterona |
HUP0600409A3 (en) * | 2006-05-15 | 2008-05-28 | Univ Szegedi | Izatin and it's derivatives for use as a medicine |
TWI315304B (en) * | 2006-08-31 | 2009-10-01 | Univ Taipei Medical | Indoline-sulfonamides compounds |
ES2457418T3 (es) * | 2007-07-16 | 2014-04-25 | Abbvie Inc. | Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas |
EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
ES2747839T3 (es) * | 2013-10-30 | 2020-03-11 | Shanghai hengrui pharmaceutical co ltd | Derivados de pirazolopirimidona o de pirrolotriazona, método de preparación de los mismos, y aplicaciones farmacéuticas de los mismos |
CN104387312B (zh) * | 2014-11-27 | 2017-02-22 | 天津坤健生物制药有限公司 | 一种3‑硫代肼基取代吲哚酮类衍生物及其制备方法与应用 |
CN104402794B (zh) * | 2014-11-27 | 2017-11-10 | 天津坤健生物制药有限公司 | 一种3‑芳基肼取代吲哚酮类衍生物及其制备方法与应用 |
AU2016338679B2 (en) | 2015-10-16 | 2021-05-06 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
CN111620808B (zh) * | 2020-06-29 | 2023-08-11 | 安徽师范大学 | 一种2-醛基吲哚类化合物及其制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE911063C (de) | 1951-10-14 | 1954-05-10 | Bayer Ag | Verfahren zur Herstellung thioindigoider Farbstoffe |
AT290523B (de) * | 1962-01-05 | 1971-06-11 | Merck & Co Inc | Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren |
JPS5283452A (en) * | 1975-12-30 | 1977-07-12 | Toray Ind Inc | Preparation of compound having prostaglandin-like activities |
US4677112A (en) * | 1984-02-02 | 1987-06-30 | Warner-Lambert Company | 1,2,3,4-tetrahydro-2-oxo-8-quinolineacetic and -propanoic acids and derivatives as cognition activators |
JP2846418B2 (ja) | 1990-06-27 | 1999-01-13 | エーザイ株式会社 | ナフタレン誘導体 |
AU654140B2 (en) * | 1990-07-31 | 1994-10-27 | Lilly Industries Limited | N-benzyl indoles, processes for their preparation or pharmaceutical compositions containing them |
US5281593A (en) * | 1990-07-31 | 1994-01-25 | Lilly Industries Limited | Certain indole derivatives useful as leukotriene antagonists |
JP3334087B2 (ja) * | 1990-09-10 | 2002-10-15 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 選択的ロイコトリエンb▲4▼拮抗剤活性を示す置換された二環式アリール化合物 |
CA2062587A1 (en) * | 1991-03-11 | 1992-09-12 | Toshiaki Kumazawa | Indole derivatives |
NZ250609A (en) * | 1992-12-28 | 1995-07-26 | Sankyo Co | Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments |
GB9317764D0 (en) * | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
WO1997024334A1 (fr) * | 1995-12-28 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Derives du benzimidazole |
CA2262569A1 (en) * | 1996-08-09 | 1998-02-19 | Norihito Ohi | Benzopiperidine derivatives |
ZA984040B (en) * | 1997-05-15 | 1998-11-20 | Ono Pharmaceutical Co | Benzenesulfonamide compounds |
WO1999011255A1 (fr) * | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Regulateurs du recepteur active par les agents de proliferation des peroxysomes |
US6242493B1 (en) * | 1998-03-13 | 2001-06-05 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
AU3053199A (en) * | 1998-04-01 | 1999-10-25 | Ono Pharmaceutical Co. Ltd. | Fused thiophene derivatives and drugs containing the same as the active ingredient |
US6380249B1 (en) * | 1998-06-03 | 2002-04-30 | Merck & Co., Inc. | HIV integrase inhibitors |
US6207664B1 (en) * | 1998-11-25 | 2001-03-27 | Pfizer Inc. | Squalene synthetase inhibitor agents |
WO2000051608A1 (en) * | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
US6492408B1 (en) * | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
MXPA03007765A (es) | 2001-03-01 | 2003-12-08 | Shionogi & Co | Compuestos heteroarilo que contienen nitrogeno, que tienen actividad inhibitoria contra virus de inmunodeficiencia humana integrasa. |
JP2003034691A (ja) * | 2001-05-15 | 2003-02-07 | Takeda Chem Ind Ltd | 縮合イミダゾリジン誘導体、その製造法及び用途 |
KR20040022238A (ko) | 2001-08-09 | 2004-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제 |
NZ554491A (en) * | 2004-10-12 | 2009-07-31 | Decode Genetics Ehf | Sulfonamide peri-substituted bicyclics for occlusive artery disease |
-
2005
- 2005-10-11 RU RU2007115522/04A patent/RU2007115522A/ru not_active Application Discontinuation
- 2005-10-11 JP JP2007536821A patent/JP2008515981A/ja active Pending
- 2005-10-11 CN CNA2005800426696A patent/CN101076531A/zh active Pending
- 2005-10-11 NZ NZ554492A patent/NZ554492A/en not_active IP Right Cessation
- 2005-10-11 CA CA002583828A patent/CA2583828A1/en not_active Abandoned
- 2005-10-11 MX MX2007004527A patent/MX2007004527A/es active IP Right Grant
- 2005-10-11 EP EP05809947A patent/EP1814881A2/en not_active Withdrawn
- 2005-10-11 US US11/247,431 patent/US7714017B2/en not_active Expired - Fee Related
- 2005-10-11 AU AU2005295821A patent/AU2005295821A1/en not_active Abandoned
- 2005-10-11 SG SG200906803-2A patent/SG156636A1/en unknown
- 2005-10-11 WO PCT/US2005/036574 patent/WO2006044415A2/en active Application Filing
-
2007
- 2007-04-11 IL IL182490A patent/IL182490A0/en unknown
- 2007-05-02 NO NO20072289A patent/NO20072289L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005295821A1 (en) | 2006-04-27 |
US20060142355A1 (en) | 2006-06-29 |
SG156636A1 (en) | 2009-11-26 |
RU2007115522A (ru) | 2008-10-27 |
CN101076531A (zh) | 2007-11-21 |
EP1814881A2 (en) | 2007-08-08 |
CA2583828A1 (en) | 2006-04-27 |
US7714017B2 (en) | 2010-05-11 |
JP2008515981A (ja) | 2008-05-15 |
WO2006044415A2 (en) | 2006-04-27 |
NZ554492A (en) | 2010-07-30 |
WO2006044415A3 (en) | 2006-08-10 |
IL182490A0 (en) | 2007-09-20 |
MX2007004527A (es) | 2007-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072289L (no) | Karboksylerte pers-substituerte bicykliske forbindelser for okklusiv arteriesykdom | |
IL182488A0 (en) | Sulfonamide peri-substituted bicyclics for occlusive artery disease | |
MY137040A (en) | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | |
NO20045589L (no) | Nye forbindelser | |
NO20072269L (no) | Arylsulfonamid peri-substituerte bicykliske forbindelser for okklusiv arteriesykdom | |
NO20083561L (no) | Forbindelser for behandling av inflammatoriske forstyrrelser | |
NO20070855L (no) | Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer. | |
DE60107687D1 (de) | Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden | |
WO2007050783A3 (en) | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension | |
EA200700717A1 (ru) | Сульфонамиды | |
WO2012004678A3 (en) | Serine protease inhibitors | |
IS8516A (is) | Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum | |
NO20071343L (no) | Substituerte fenylaminotiazoler og anvendelse derav | |
WO2007038620A3 (en) | Milnacipran for the long-term treatment of fibromyalgia syndrome | |
WO2006076370A3 (en) | Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions | |
WO2010046713A8 (en) | Methods for preparing heterocyclic rings | |
NO20074047L (no) | Ny fremgangsmate for fremstilling av substituerte indoler | |
DK1817326T3 (da) | Industriel fremgangsmåde til fremstilling af 17-hydroxy-6-beta, 7-beta, 15-beta, 16-beta-bismethylen-3-oxo-17-alpha-pregn-4-en-21-carboxylsyre-gamma-lacton og nøglemellemprodukter for denne fremgangsmåde | |
NO20075599L (no) | Profylaktisk eller terapeutisk middel mot depresjon eller angstforstyrrelser | |
ATE399557T1 (de) | Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen | |
WO2004111047A3 (en) | Cycloalkanepyrrolopyridines as dp receptor antagonists | |
WO2004017949A3 (de) | Prophylaxe und therapie von infektionserkrankungen mit amitryptilin oder imipramin oder desipramin oder fgf oder einem anticeramid antikörper oder cyclodextrin oder nystatin oder filipin | |
ATE372330T1 (de) | N-sulfonylurea-apoptosis-förderer | |
BR112016012531A2 (pt) | produção de alcenos a partir de ácidos 3-hidroxicarboxílicos através de ácidos 3-hidroxicarboxil-nucleotidílicos? | |
EA200400438A1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |